Dt Cloud Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Nasdaq denied DT Cloud Acquisition’s continued listing request, setting a potential trading suspension for November 21, 2025 unless the company appeals.
DT Cloud Acquisition Corporation entered a private placement for its business combination with Maius Pharmaceutical, while simultaneously receiving a Nasdaq deficiency notice for low market value of publicly held shares.
DT Cloud Acquisition Corporation received Nasdaq delisting notices for low market value and public shares, while shareholders approved an extension for its business combination deadline.
DT Cloud Acquisition Corporation (DYCQ) announced the resignation of CEO Shaoke Li and the immediate appointment of CFO Guojian Chen as his successor, effective June 10, 2025.
DT Cloud Acquisition Corporation's shareholders approved a reduction in the monthly extension fee and related amendments, while the company faced substantial share redemptions and entered into new voting agreements to retain capital for its business combination with Maius Pharmaceutical Co., Ltd.
DT Cloud Acquisition Corporation amends its voting agreement to issue additional SPAC rights to shareholders who redeem 75% of their shares and forego redemption rights on the remaining 25%.
DT Cloud Acquisition Corporation announces the postponement of its Extraordinary General Meeting (EGM) and the related redemption right deadline.
DT Cloud Acquisition Corporation is amending its extension fee and entering into voting agreements with certain shareholders to facilitate an extension for consummating its initial business combination.
8-K: DT Cloud Acquisition Corporation Shareholders Approve Extension to Consummate Business Combination
DT Cloud Acquisition Corporation's shareholders voted to approve an extension to the period for completing a business combination at an extraordinary general meeting held on April 23, 2025.
DT Cloud Acquisition Corporation announces the postponement of its Extraordinary General Meeting (EGM) and redemption right deadline.
DT Cloud Acquisition Corporation's shareholders approved a proposal to extend the deadline for completing a business combination to May 23, 2026, along with related trust amendments.
DT Cloud Acquisition Corporation has cancelled its upcoming extraordinary general meeting of shareholders and withdrawn the proposals under consideration.
DT Cloud Acquisition Corporation is seeking an extension to complete its initial business combination and has postponed its Extraordinary General Meeting (EGM) to February 21, 2025.
DT Cloud Acquisition Corporation postpones its shareholder meeting to February 21, 2025, and proposes a second amendment to the monthly extension fee payable by its sponsor.
8-K: DT Cloud Acquisition Corp Proposes Amendment to Monthly Extension Fee Ahead of Shareholder Meeting
DT Cloud Acquisition Corporation is seeking shareholder approval to increase the monthly extension fee payable by its Sponsor to $70,000, amending a previous proposal.
DT Cloud Acquisition Corporation enters into a subscription agreement for a private placement of 30,000 ordinary shares at $10.00 per share, totaling $300,000, to a single investor.
DT Cloud Acquisition Corporation and Maius Pharmaceutical Co., Ltd. have entered into a definitive agreement for a business combination that will result in Maius becoming a publicly listed company on Nasdaq.
DT Cloud Acquisition Corporation has signed a non-binding letter of intent to acquire Shanghai Maius Pharmaceutical Technology, a biopharmaceutical R&D company.
DT Cloud Acquisition Corporation will allow separate trading of its ordinary shares and rights starting April 12, 2024, previously bundled as units.
DT Cloud Acquisition Corporation successfully completed its initial public offering, raising $69 million to pursue a business combination.
DT Cloud Acquisition Corporation successfully closed its initial public offering, raising $69 million, which included the full exercise of the underwriters' over-allotment option.